Genmab (GMAB) said the European Commission approved TEPKINLY (epcoritamab) with lenalidomide and rituximab (TEPKINLY + R2) for adults with relapsed/refractory follicular lymphoma. The approval is described as the first in this regimen, a meaningful positive regulatory milestone for the therapy and a potential catalyst for sentiment around Genmab’s oncology pipeline.
Genmab (GMAB) said the European Commission approved TEPKINLY (epcoritamab) with lenalidomide and rituximab (TEPKINLY + R2) for adults with relapsed/refractory follicular lymphoma. The approval is described as the first in this regimen, a meaningful positive regulatory milestone for the therapy and a potential catalyst for sentiment around Genmab’s oncology pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
